We are pleased to announce the launch of StrateGIST 3, a randomized, multicenter, open-label Phase III study evaluating IDRX-42 (GSK6042981) versus sunitinib in participants with metastatic and/or unresectable gastrointestinal stromal tumors (GIST) following prior treatment with imatinib.
About the Study
Gastrointestinal stromal tumors are the most common type of soft tissue sarcoma of the gastrointestinal tract. Although imatinib remains the standard first-line therapy, many patients eventually experience disease progression, underscoring the need for additional therapeutic strategies.
StrateGIST 3 is designed to compare the efficacy and safety of IDRX-42 with sunitinib, the current standard second-line treatment option. The study is being conducted across multiple centers.
Who Can Participate?
Patients who meet eligibility criteria may have the opportunity to participate in this important research initiative.
Why Join?
- Access to specialized care and close monitoring
- Be part of an innovative study that could shape future treatments
- Help researchers better understand GIST
For further details regarding eligibility, study sites, or referral information, please contact our team.
Let’s advance the future of GIST treatment together!
